slightbourne@noblecapitalmarkets.com, Author at Channelchek

Release – Eledon Announces Updated Data from Investigator-Initiated Islet Transplant Trial of Tegoprubart in Patients with Type 1 Diabetes (T1D) at UChicago Medicine

Posted on June 8, 2026June 8, 2026 by [email protected]

June 8, 2026

– All 12 patients in study (100%) achieved insulin independence, producing their own insulin and no longer requiring exogenous insulin therapy to manage their T1D

– All 12 patients also achieved an HbA1c below 6.5%, with a mean most recent HbA1c of approximately 5.4%, representing an approximately 2.6% average improvement in HbA1c from baseline

– No severe hypoglycemic episodes were reported post-transplant, compared with a history of recurrent severe hypoglycemic events prior to transplantation in all enrolled patients

IRVINE, Calif., June 08, 2026 (GLOBE NEWSWIRE) — Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN) today announced updated results from an investigator-initiated trial evaluating tegoprubart, its investigational anti-CD40L antibody, as part of a calcineurin inhibitor-free immunosuppression regimen in patients with type 1 diabetes undergoing allogeneic islet cell transplantation at the University of Chicago Medicine Transplant Institute. The results were presented by trial investigator Piotr Witkowski, M.D., Ph.D., Director of the Pancreas and Islet Transplant Program at UChicago Medicine, at the American Diabetes Association 86th Scientific Sessions, taking place June 5-9, 2026, in New Orleans, Louisiana.

All patients treated in the study (n=12) showed rapid improvement in glycemic control following islet transplantation and treatment with tegoprubart, with stable islet graft function observed across the cohort over a median and maximum post-transplant follow-up period of 8 and 22 months, respectively. All 12 patients achieved insulin independence, meaning that they no longer needed chronic, exogenous insulin therapy to manage their T1D. Also, all patients demonstrated a most recent hemoglobin A1C (“HbA1c”) below the diabetic threshold of 6.5%, with a mean most recent HbA1c of approximately 5.4% across the cohort.

While all patients enrolled reported recurrent severe hypoglycemic events pre-transplant, no severe hypoglycemic episodes were reported following transplantation. Severe hypoglycemia is a serious complication of type 1 diabetes that may require emergency medical intervention and can cause loss of consciousness, seizures, injury, or death. Recurrent severe hypoglycemic episodes can significantly impact patients’ daily activities and quality of life.

Higher levels of post-transplant islet cell engraftment were observed with the tegoprubart-based immunosuppression regimen than in historical patients treated with a tacrolimus-based immunosuppression regimen at UChicago Medicine. There were no rejection episodes, and no patients developed de novo donor-specific HLA antibodies. Tegoprubart-based immunosuppression was generally well tolerated, with immunosuppression-related adverse events generally successfully treated by lowering the mycophenolic acid dose, if necessary. Additionally, no evidence of nephrotoxicity, hypertension or neurotoxicity, which are commonly associated with tacrolimus-based immunosuppression regimens, was observed. These findings further support the potential of CD40L blockade to enable effective islet graft protection while avoiding the toxicities of calcineurin inhibitors such as tacrolimus.

The investigator-initiated pilot study enrolled 12 adults with long-standing T1D undergoing allogeneic islet transplantation at UChicago Medicine with a median duration of diabetes of approximately 33 years and mean HbA1c of approximately 8.0% prior to transplantation. Participants received tegoprubart, as part of a calcineurin inhibitor-free immunosuppression regimen. Calcineurin inhibitors such as tacrolimus are commonly used to prevent transplant rejection but can be associated with kidney toxicity, hypertension, neurological side effects, and harm to insulin-producing islet cells, limiting their suitability for long-term use in patients with T1D receiving an islet cell transplant.

“T1D patients have been waiting decades for a potential functional cure, and it is exciting to see the progress being made in that direction through the emerging promise of tegoprubart,” said David-Alexandre C. Gros, M.D., Chief Executive Officer of Eledon. “For people who have difficulty managing T1D, a regimen that may protect an islet cell graft without the long-term burden associated with calcineurin inhibitors, the current standard of care, could be transformational. We are proud to support this important research effort led by Dr. Witkowski and the team at UChicago Medicine. We also look forward to working closely with the FDA towards our goal of receiving regulatory guidance on a path to market for tegoprubart in islet cell transplantation later this year.”

“Insulin independence without the burden of traditional immunosuppression has long been one of cell replacement therapy’s biggest goals,” said Aaron Kowalski, Ph.D., Chief Executive Officer of Breakthrough T1D. “Results like these show that this goal is becoming increasingly achievable. Breakthrough T1D is proud to fund this important study.”

This UChicago Medicine-initiated clinical trial is funded by Breakthrough T1D, with initial support from The Cure Alliance. Breakthrough T1D has also committed to fund a second study evaluating tegoprubart as part of a calcineurin inhibitor-free immunosuppression drug regimen to prevent islet transplant rejection in individuals with T1D and chronic kidney disease.

About Islet Transplantation for Type 1 Diabetes

Pancreatic islet transplantation is a minimally invasive procedure developed to provide blood glucose control for subjects with type 1 diabetes and minimize or eliminate dependence on insulin. During the procedure, pancreatic islets containing insulin-producing beta cells are isolated from the pancreas of a deceased organ donor and infused through a small catheter into the patient’s liver. The islet cells lodge in small blood vessels in the liver and release insulin. After the procedure, subjects remain on immunosuppression therapy to prevent transplant rejection.

About Eledon Pharmaceuticals and tegoprubart

Eledon Pharmaceuticals, Inc. is a clinical stage biotechnology company that is developing immune-modulating therapies for the management and treatment of life-threatening conditions. The Company’s lead investigational product is tegoprubart, an anti-CD40L antibody with high affinity for the CD40 Ligand, a well-validated biological target that has broad therapeutic potential. The central role of CD40L signaling in both adaptive and innate immune cell activation and function positions it as an attractive target for non-lymphocyte depleting, immunomodulatory therapeutic intervention. The Company is building upon a deep historical knowledge of anti-CD40 Ligand biology to conduct preclinical and clinical studies in kidney allograft transplantation, xenotransplantation, islet cell transplantation, liver allograft transplantation and amyotrophic lateral sclerosis (ALS). Eledon is headquartered in Irvine, California. For more information, please visit the Company’s website at www.eledon.com.

Follow Eledon Pharmaceuticals on social media: LinkedIn; X

Forward-Looking Statements

This press release contains forward-looking statements that involve substantial risks and uncertainties. Any statements about the company’s planned clinical trials, the development of product candidates, expected or future results of tegoprubart trials and its ability to prevent rejection in connection with islet cell transplantation, as well as other statements containing the words “believes,” “anticipates,” “plans,” “expects,” “estimates,” “intends,” “predicts,” “projects,” “targets,” “looks forward,” “could,” “may,” and similar expressions, constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are inherently uncertain and are subject to numerous risks and uncertainties, including: risks relating to the safety and efficacy of our drug candidates; risks relating to clinical development timelines, including interactions with regulators and clinical sites, as well as patient enrollment; and risks relating to costs of clinical trials and the sufficiency of the company’s capital resources to fund planned clinical trials. Actual results may differ materially from those indicated by such forward-looking statements as a result of various factors. These risks and uncertainties, as well as other risks and uncertainties that could cause the company’s actual results to differ significantly from the forward-looking statements contained herein, are discussed in our quarterly 10-Q, annual 10-K, and other filings with the U.S. Securities and Exchange Commission, which can be found at www.sec.gov. Any forward-looking statements contained in this press release speak only as of the date hereof and not of any future date, and the company expressly disclaims any intent to update any forward-looking statements, whether as a result of new information, future events or otherwise.

Investor Contact:

Stephen Jasper
Gilmartin Group
(858) 525 2047
[email protected]

Media Contact:

Jenna Urban
CG Life
(212) 253 8881
[email protected]

Source: Eledon Pharmaceuticals

The Russell Reconstitution Enters Lock-Down Today. Here Is What Happens Next and Why It Matters

Posted on June 8, 2026June 8, 2026 by [email protected]

If you have been following the small and microcap market closely over the past several weeks, today marks a significant checkpoint. Monday June 8 is the official “lock-down” date in the 2026 Russell US Indexes reconstitution schedule — the point at which preliminary membership changes are considered final and the market begins positioning in earnest for one of the highest trading volume events of the entire year.

The reconstitution itself happens after the close on Friday June 26. Markets open on Monday June 29 with the newly rebalanced indexes in effect. Between now and then, every dollar benchmarked to the Russell family of indexes — which collectively underpin trillions in passive investment products, ETFs, and institutional mandates — begins its systematic repositioning process.

What the 2026 Reconstitution Actually Shows

The preliminary data released by FTSE Russell on May 22 tells a specific story about where the US equity market stands after a year of significant movement. The total market capitalization of the Russell 3000 — the broad index tracking the largest 3,000 US-listed companies — rose 29% year over year to $75.6 trillion as of the April 30 rank day. That growth was driven primarily by continued mega-cap strength, with the ten largest companies in the index growing their combined market cap 47% to $26.4 trillion. But the preliminary data also confirms what we have been covering here throughout May and early June: small cap companies posted strong gains of their own, and market breadth is genuinely improving.

The migration numbers tell the story at the company level. Sixty-two companies are graduating from the Russell 2000 to the Russell 1000 — meaning they have grown large enough to cross into large cap territory. Of those, technology and industrials companies account for the largest share with 18 additions each, followed by healthcare with seven. At the same time, 237 companies are being added to the Russell 2000 this cycle, including 37 moving down from the Russell 1000 and a significant cohort of healthcare names — 87 in total — joining the small cap index.

Why Lock-Down Day Matters for Active Investors

The mechanics of reconstitution create predictable price dynamics that active investors in the small cap space have historically used to their advantage. Stocks confirmed to be added to the Russell 2000 or Russell 1000 attract forced buying from passive funds and ETFs that must replicate the index composition. Stocks being deleted face the opposite — forced selling by the same funds regardless of underlying fundamentals. Both effects tend to be most pronounced in the days immediately before and after reconstitution day itself.

June 26 consistently ranks among the highest single-day trading volume events of the year precisely because of the scale of simultaneous repositioning happening across the index. This year that dynamic is amplified by an additional layer of significance.

A Historic Change to the Reconstitution Process

2026 marks the first time since 1989 that FTSE Russell is running a semi-annual reconstitution schedule. Rather than one annual rebalance in June, the indexes will now be updated twice a year — with a second reconstitution scheduled after the close on Friday December 11, 2026. The shift is designed to more accurately capture the pace at which companies are moving across market cap segments in today’s environment and to reduce the distortive impact of concentrating all index-related trading into a single annual event.

For small and microcap investors, the semi-annual schedule has a direct implication: the window between when a company’s fundamentals change and when those changes are reflected in index composition is now meaningfully shorter. Companies growing rapidly into small cap territory, or contracting out of it, will be captured and repositioned faster than at any point in the past 37 years.

We have been covering the small cap outperformance story throughout May and into June — from the valuation discount that still exists relative to large caps, to the record microcap returns that most investors have not fully noticed. The Russell reconstitution on June 26 is the structural mechanism through which much of that market evolution gets formally recognized and institutionally repriced. Mark the date.

Star Equity Holdings, Inc. (STRR) – Noble Virtual Conference June 2026

Posted on June 8, 2026June 8, 2026 by [email protected]

Monday, June 08, 2026

Joe Gomes, CFA, Managing Director, Equity Research Analyst, Generalist , Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Noble Virtual Conference. Star Equity CEO Jeff Eberwein presented at the Noble Virtual Conference. Highlights included the GEE Group investment, efforts to monetize non-cash flowing assets, and future financial goals. A rebroadcast is available at https://www.channelchek.com/videos/star-equity-holdings-strr-noble-capital-markets-virtual-conference-replay-june-2026.

GEE Group. Star remains very involved in GEE Group. Star already has proposed to acquire the firm, and last week Star issued a press release announcing a director nomination to GEE’s board and calling for GEE shareholders to vote to remove the existing GEE directors. Star’s nominee, Rick Coleman, is currently COO of Star and previously was CEO of staffing company Command Center, where he implemented policies that drove significant shareholder value creation.

Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision.

SKYX Platforms (SKYX) – Noble Virtual Conference June 2026

Posted on June 8, 2026June 8, 2026 by [email protected]

Monday, June 08, 2026

Joe Gomes, CFA, Managing Director, Equity Research Analyst, Generalist , Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Noble Virtual Conference. SKYX Platforms CEO Leonard Sokolow presented at the Noble Virtual Conference. Highlights included regulatory efforts, new agreements, and product introductions. A rebroadcast is available at https://www.channelchek.com/videos/skyx-platforms-skyx-noble-capital-markets-virtual-conference-replay-june-2026.

Regulatory. SKYX continues to pursue mandatory regulation for the ceiling outlet receptacle, or weight support ceiling receptacle, as classified by the National Electric Code. SKYX has some heavyweights behind the push here, and we would not be surprised to see some type of resolution in the near term. Although mandatory classification could be a game-changer for the Company, the demonstrable savings in installation time, ease of swap-outs, and harm reduction benefits of SKYX’s system are sufficient to drive results, in our opinion.

Get the Full Report

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

ONE Group Hospitality (STKS) – Noble Virtual Conference June 2026

Posted on June 8, 2026June 8, 2026 by [email protected]

Monday, June 08, 2026

Joe Gomes, CFA, Managing Director, Equity Research Analyst, Generalist , Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Noble Virtual Conference. ONE Group Hospitality CEO Manny Hilario and CFO Nicole Thaung presented at the Noble Virtual Conference. Highlights included accelerating SSS, pursuing capital-efficient growth, and optimizing the portfolio. A rebroadcast is available at https://www.channelchek.com/videos/the-one-group-hospitality-stks-noble-capital-markets-virtual-conference-replay-june-2026.

SSS. Improving Same Store Sales remains a key focus of management. In the first quarter of 2026, all brands saw sequential SSS growth, with STK reporting positive SSS and Benihana flat SSS. Even the Grill concepts have experienced a significant improvement in SSS over the past three quarters. ONE Group’s focus on providing value, the vibe experience, execution, and targeted marketing is paying dividends in a tough operating environment.

Get the Full Report

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

Broadcom’s 15% Single-Day Plunge Took $300 Billion Off the Table

Posted on June 8, 2026June 8, 2026 by [email protected]

The semiconductor sector just recorded one of its worst sessions of 2026. Broadcom fell approximately 15% Thursday after reporting fiscal second quarter results that beat earnings estimates but failed to raise full-year guidance — a distinction that matters enormously when a stock has run more than 90% year to date. The selloff spread immediately across the chip space. Micron dropped more than 6%, Marvell fell 5%, AMD declined 6%, and ARM Holdings lost nearly 9%. The Philadelphia Semiconductor Index, which had climbed 92% in 2026 heading into this week, shed more than 5% in a single session — one of its largest single-day drops since early 2025.

By Friday morning losses were extending. The two-day chip sector rout has now erased hundreds of billions in large cap market value in what has become one of the most closely watched sector corrections of the year.

What Actually Happened With Broadcom

The Broadcom report was not a fundamental collapse. Revenue for the quarter came in at $22.19 billion, up 48% year over year, with adjusted earnings per share of $2.44 beating the consensus estimate of $2.40. AI chip revenue grew more than 200% year over year. The company maintained its long-term target of semiconductor revenue exceeding $100 billion next fiscal year.

What rattled investors was a combination of two things. First, Q3 AI chip revenue guidance of approximately $16 billion came in below market expectations of $17.2 billion. Second, management reiterated rather than raised its 2026 full-year guidance — a significant signal to a market that had been pricing in continuous upward revisions. Separately, Broadcom is beginning to lose market share in supplying custom AI chips to Alphabet, with its share of Google’s tensor processing unit business expected to decline meaningfully through 2028 as a Taiwan-based competitor gains ground.

The underlying business did not break. Market expectations simply caught up with where the stock was trading. That is a valuation story, not a demand story — and that distinction matters considerably for how investors should interpret what happened.

Why This Matters for Smaller Semiconductor Companies

The selloff at the large cap level does not reflect a change in the fundamental demand environment driving chip sector growth. The five largest hyperscalers — Amazon, Alphabet, Meta, Microsoft, and Oracle — are collectively projecting $725 billion in capital expenditures in 2026, up 77% from the prior year’s already record-breaking level. Total AI infrastructure spending is projected at $7.6 trillion between 2026 and 2031. That capital does not flow exclusively through the top five chip companies. It moves through hundreds of suppliers, component manufacturers, and technology providers operating at every layer of the AI hardware stack.

Specialty materials companies, advanced packaging providers, power management chip designers, optical component manufacturers, and printed circuit board makers all sit in the downstream path of hyperscaler capital expenditure. Many of those companies operate well below the $2 billion market cap threshold and have not experienced the same run-up in valuations that left Broadcom, Micron, and AMD exposed to a guidance disappointment.

The pattern playing out this week is one the semiconductor sector has seen before. Extended rallies in large cap names draw increasing analyst scrutiny and tighter expectations — and when any element of those expectations goes unmet, the correction is sharp and immediate. Smaller companies in the same supply chain, carrying lower valuations and more modest expectations, tend to absorb that volatility differently.

For investors in smaller semiconductor names, Thursday’s large cap selloff is worth examining as a reference point rather than a warning signal. The AI infrastructure buildout that created the demand environment these companies operate in did not change on Thursday evening. The stock prices of a handful of mega cap chip companies did.

May Payrolls Nearly Double Expectations at 172,000

Posted on June 5, 2026June 5, 2026 by [email protected]

The US labor market delivered its strongest headline surprise of 2026 on Friday morning. The Bureau of Labor Statistics reported the economy added 172,000 jobs in May, nearly doubling the 88,000 that economists surveyed by Bloomberg had anticipated. The unemployment rate held steady at 4.3%. The report landed alongside upward revisions to prior months: April’s original 115,000 payroll figure was revised to 179,000, and March was adjusted to 214,000, marking the first monthly gain above 200,000 since early 2024.

On the surface, the numbers paint a picture of a labor market that has defied repeated predictions of deterioration. Beneath the surface, the report is more complicated.

May’s gains were notably broad-based rather than concentrated in the healthcare sector, which has been the primary engine of US job growth for the better part of two years. Leisure and hospitality led all sectors with 70,000 new positions, followed by local government at 55,000 and healthcare at approximately 35,000. Food services and drinking places contributed 48,000 of the leisure and hospitality total.

That sectoral breakdown matters for context. A Bank of America Institute analysis released this week found that while May payroll growth accelerated, much of the underlying strength appears to be concentrated in lower-income job categories. Average hourly earnings for food services workers, one of the month’s largest contributing sectors, stand at $21.86 according to government data. Across the full economy, average hourly earnings grew 3.4% year over year in May, a pace that continues to track below the current rate of consumer price inflation.

The Federal Reserve’s Beige Book, released Wednesday, reinforced this picture at the ground level. Eleven of the Fed’s 12 districts described a low-hire, low-fire environment, with workers increasingly reluctant to change jobs amid broader economic uncertainty. The report noted that hiring across most districts remained selective and primarily focused on critical roles or attrition replacement rather than expansion.

For investors tracking monetary policy, Friday’s report arrives at a sensitive moment. Federal Reserve Chair Kevin Warsh presides over his first FOMC meeting June 16-17, and a labor market printing nearly double expectations gives the committee additional justification to hold rates steady. Markets had already priced in more than an 80% probability of a June hold heading into this week. A 172,000 payroll print is unlikely to change that calculus and may further push rate cut expectations into 2027.

The jobs report delivers a split verdict for the sub-$2 billion market cap space. The 70,000 jobs added in leisure and hospitality represent real incremental consumer activity that flows directly through to small cap restaurant operators, regional hospitality companies, and travel-adjacent businesses that have been managing through an uneven demand environment. More workers employed in discretionary spending sectors is a near-term tailwind for these names.

The counterweight is the Fed. A stronger-than-expected labor market that keeps the central bank on hold extends the timeline for the rate relief that smaller, variable-rate borrowers have been waiting on. Until wage growth catches up with inflation and gives the Fed room to ease, the rate environment for small cap balance sheets remains a structural headwind regardless of how many jobs the economy adds each month.

V2X (VVX) – Lowering Cost of Capital; More Flexibility

Posted on June 4, 2026June 4, 2026 by [email protected]

Thursday, June 04, 2026

Joe Gomes, CFA, Managing Director, Equity Research Analyst, Generalist , Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Term Loan Repricing. V2X successfully repriced its approximately $869 million First Lien Term Loan. The repricing improves the applicable interest rate to SOFR plus an applicable margin of 2.0%, with an additional 25 basis-point reduction upon achieving specific corporate credit ratings of Ba3 (stable outlook) from Moody’s and BB (stable outlook) from S&P. The repricing also reduced the SOFR floor from 0.75% to 0.00%.

Implications. The transaction immediately lowers the Company’s borrowing costs and positions V2X to realize interest savings as the Company’s financial profile continues to strengthen. While the actual amount of interest savings will depend on SOFR rates, the transaction enhances the Company’s cost of capital and increases value for shareholders, in our view. With the closing, V2X has now successfully repriced its First Lien Term Loan four times since October 2023, highlighting the ongoing improvement in the Company’s financial profile, as well as the increased opportunity set, in our opinion.

Get the Full Report

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

Kelly Services (KELYA) – Are the Shoots Getting Greener?

Posted on June 4, 2026June 4, 2026 by [email protected]

Thursday, June 04, 2026

Joe Gomes, CFA, Managing Director, Equity Research Analyst, Generalist , Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Labor Market Sustained Momentum? U.S. private employers added 122,000 jobs in May, according to ADP, exceeding the 120,000 consensus estimate and up from April’s 105,000 revised number. ADP noted, “The labor market continues to show sustained momentum going into the summer hiring season.” While still early, these improving green shoots provide encouragement for the second half improvement in Kelly’s business, in our view.

Broad-Based. ADP noted the hiring was more broad-based in May than in the last few years, with eight of the ten supersectors ADP tracks posting positive momentum. Gains were led by the education and health care sectors.

Get the Full Report

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

Release – Cocrystal Pharma Appoints James Sapirstein, Biopharma Industry Leader with Extensive Antiviral Development Experience, as Chief Executive Officer

Posted on June 3, 2026June 3, 2026 by [email protected]

June 03, 2026

Download as PDF

BOTHELL, Wash., June 03, 2026 (GLOBE NEWSWIRE) — Cocrystal Pharma Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”), a clinical-stage biotechnology company developing novel therapeutics to meet the growing need for effective, safe antiviral treatments, has appointed James Sapirstein Chief Executive Officer, effective immediately. The Company also plans to appoint Mr. Sapirstein as a member of the Board of Directors. He has extensive pharmaceutical industry leadership and development experience. Mr. Sapirstein replaces Sam Lee and Jim Martin, who served as Co-Chief Executive Officers. Sam Lee will continue as President and transition to Chief Scientific Officer, and Jim Martin will continue as Chief Financial Officer.

“James brings the right experience in the biopharma business as we’re accelerating the advancement of multiple clinical programs,” said Roger Kornberg, Ph.D., Chairman of Cocrystal Pharma. “We have known him for many years, and our management team and board are appreciative of his decision to join us as Chief Executive Officer.”

Mr. Sapirstein commented, “Cocrystal’s pipeline comprises transformative antivirals developed using its structure based drug discovery platform. We are well positioned with the right technology and team to create meaningful benefits for patients as well as our shareholders. The potential to address the need for new antivirals is highly motivating for me with my product development and launch background.”

Mr. Sapirstein has participated in or led 23 product launches. He has also driven numerous business development transactions. Mr. Sapirstein was Chief Executive Officer of Contravir Pharmaceuticals, served as the founding Chief Executive Officer of Tobira Therapeutics, and as Executive Vice President, Metabolic and Endocrinology, for Serono Laboratories.

Earlier in his career, he held senior marketing and commercialization positions, at Gilead Sciences and director of international marketing of the infectious disease division at Bristol Myers Squibb.

Mr. Sapirstein is a member of several industry boards and previously served as Chairman of BioNJ as well as Biotechnology Innovation Organization board member for more than a decade. He is also a founding member of the board of advisors of the Miami Biotech Collective.

About Cocrystal Pharma’s Structure-Based Drug Discovery Platform

Cocrystal Pharma is leveraging its structure based drug discovery platform technology to design next generation antiviral candidates that precisely target viral replication mechanisms. By binding to highly conserved regions of viral enzymes, the Company’s compounds aim to maintain potency against mutating strains while minimizing off target effects, offering potentially safer, broad spectrum antiviral solutions. This approach streamlines candidate identification and optimization, enabling more rapid progression of promising therapies with robust resistance and safety profiles.

The Company’s platform provides a three dimensional structure of inhibitor complexes at near-atomic resolution, providing immediate insight to guide Structure Activity Relationships. This helps identify novel binding sites and enables a rapid turnaround of structural information through highly automated X-ray data processing and refinement. This technology permits the development of novel broad spectrum antivirals.

About Cocrystal Pharma

Cocrystal Pharma Inc. is a clinical stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication process of noroviruses, influenza viruses, coronaviruses (including SARS-CoV-2), and hepatitis C viruses. Cocrystal employs unique structure based technologies to create viable antiviral drugs. For more information, visit www.cocrystalpharma.com.

Release – V2X to Generate Interest Expense Savings Through Successful Term Loan Repricing

Posted on June 3, 2026June 3, 2026 by [email protected]

June 03, 2026

RESTON, Va., June 3, 2026 /PRNewswire/ — V2X, Inc. (NYSE: VVX), today announced the successful repricing of its approximately $869 million First Lien Term Loan. The repricing improves the applicable interest rate to SOFR plus an applicable margin of 2.0%, with an additional 25 basis-point-reduction upon achieving specific corporate credit ratings of Ba3 (stable outlook) from Moody’s and BB (stable outlook) from S&P. The repricing also reduced the SOFR floor from 0.75% to 0.00%.

“This transaction immediately lowers our borrowing costs and positions us to realize interest savings as our financial profile continues to strengthen,” said Shawn Mural, Senior Vice President and Chief Financial Officer of V2X. “The repricing provides a 25-basis-point reduction in our applicable margin, with the opportunity for an additional 25-basis-point reduction upon achieving and maintaining specified credit ratings. These savings are expected to drive lower interest expense, enhance our cost of capital, and increase value for shareholders.”

With the closing on Friday May 29, 2026, V2X has now successfully repriced its First Lien Term Loan four times since October 2023.

About V2X
V2X builds innovative solutions that integrate physical and digital environments by aligning people, actions, and technology. V2X is embedded in all elements of a critical mission’s lifecycle to enhance readiness, optimize resource management, and boost security. The company provides innovation spanning national security, defense, civilian, and international markets. With a global team of approximately 16,000 professionals, V2X enables mission success by injecting AI and machine learning capabilities to meet today’s toughest challenges across all operational domains.

Investor Contact
Mike Smith, CFA
Vice President, Treasury, Corporate Development and Investor Relations
[email protected]
719-637-5773

Media Contact
Angelica Spanos Deoudes
Senior Director, Corporate Communications
[email protected]
571-338-5195

Release – Cadrenal Therapeutics to Showcase Phase 3-Ready CAD-1005 and Novel 12-LOX Platform at BIO International Convention 2026 Partnering Event

Posted on June 3, 2026June 3, 2026 by [email protected]

PONTE VEDRA, Fla., June 03, 2026 (GLOBE NEWSWIRE) — Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a biopharmaceutical company advancing novel therapies for life-threatening immune and thrombotic conditions, today announced its participation in the BIO International Convention 2026 Partnering Event (BIO 2026) taking place June 22-25, 2026, at the San Diego Convention Center.

The Company’s executive management team will host partnering meetings to discuss development and commercialization opportunities for its differentiated pipeline, headlined by CAD-1005, a Phase 3-ready 12-lipoxygenase (12-LOX) inhibitor being investigated for the treatment of patients with Heparin-Induced Thrombocytopenia (HIT), and tecarfarin, a late-stage oral Vitamin K antagonist (VKA) for being investigated for the treatment of patients with conditions for which current anticoagulation profiles are ineffective or suboptimal.

“BIO 2026 comes at a pivotal moment for Cadrenal as we prepare to initiate our Phase 3 registration trial for CAD-1005,” said Quang X. Pham, Chief Executive Officer of Cadrenal Therapeutics. “With Orphan Drug and Fast Track designations from the FDA, we believe we are uniquely positioned to address the significant unmet need in HIT, a condition where no new therapies have been approved in over two decades. We look forward to engaging with potential partners who share our vision of the potential to bring this breakthrough mechanism to patients.”

Highlighting CAD-1005: A Potential First-in-Class Solution for HIT
At the forefront of Cadrenal’s portfolio is CAD-1005, the only selective 12-LOX inhibitor known to us to be currently in clinical development. CAD-1005 is being investigated to target the root cause of HIT-a severe, immune-mediated reaction to heparin that causes life-threatening blood clots and low platelet counts. Unlike current therapies that only reduce the risk of thrombotic complications, CAD-1005 is being investigated to interrupt the immune signaling feedback loop that drives the development and persistence of HIT.

The Company recently completed an End-of-Phase 2 (EOP2) meeting with the FDA, which provided guidance on the registration path for a single pivotal Phase 3 trial. This follows Phase 2 data demonstrating that CAD-1005 could reduce thrombotic events in patients with HIT.

Unlocking the Potential of the 12-LOX Platform
Beyond HIT, Cadrenal is leveraging the BIO 2026 partnering forum to explore broader applications for its proprietary 12-LOX inhibitor platform. Emerging research indicates that 12-LOX may play a central role in inflammatory signaling across high-impact disease areas, including atherosclerosis, microvascular thrombosis, and metabolic conditions such as diabetes and obesity. Additionally, 12-LOX is a potential target for therapy and prevention of cancer.

The Company’s platform represents a novel approach to modulating inflammation without the broader systemic suppression associated with traditional anti-inflammatory agents. Cadrenal aims to identify strategic collaborations to accelerate the development of its second-generation oral 12-LOX inhibitors (CAD-2000) for these chronic, large-market indications.

Tecarfarin: A Potentially Superior Anticoagulant for Complex Cases
Cadrenal will also present opportunities for tecarfarin, its late-stage oral anticoagulant. Tecarfarin is being designed with the goal of being uniquely metabolized in ways that avoid the drug-drug interactions and renal clearance issues common with warfarin and direct oral anticoagulants (DOACs). Tecarfarin has already received FDA Orphan Drug and Fast Track designations for two specific high-risk populations – patients with End-Stage Renal Disease (ESRD) and Atrial Fibrillation (AFib), and patients with implanted mechanical circulatory support devices, including Left Ventricular Assist Devices (LVADs).

About Cadrenal Therapeutics, Inc.
Cadrenal Therapeutics, Inc. is a late-stage biopharmaceutical company advancing novel therapies for life-threatening immune and thrombotic conditions. Its lead program, CAD-1005, is being researched as a first-in-class 12-LOX inhibitor for treating heparin-induced thrombocytopenia (HIT), a deadly immune-mediated thrombotic disorder. CAD-1005 has received Orphan Drug and Fast Track designations from the U.S. Food and Drug Administration, as well as orphan drug status from the European Medicines Agency. Second-generation 12-LOX oral therapeutics are also in development for chronic indications.

The Company’s broader pipeline includes tecarfarin, a late-stage oral vitamin K antagonist designed to prevent heart attacks, strokes, and deaths from blood clots in patients requiring chronic anticoagulation, including those with end-stage kidney disease and those with left ventricular assist devices, and frunexian, a parenteral Factor XIa inhibitor intended for use in acute hospital settings.

Release – MAIA Biotechnology Receives FDA Clearance to Open U.S. Enrollment in Ongoing Phase 2 THIO-101 Trial Expansion

Posted on June 3, 2026June 3, 2026 by [email protected]

June 03, 2026 9:45am EDT

Additional data from THIO-101 trial expansion studies may further support a potential Accelerated Approval filing with FDA

FDA-cleared IND updates detail latest efficacy data and enriched manufacturing protocols

CHICAGO, June 03, 2026 (GLOBE NEWSWIRE) — MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today announced that the U.S. Food and Drug Administration (FDA) has cleared an amendment to update its investigational new drug (IND) application which enables MAIA to open U.S. enrollment for the expansion of the Phase 2 THIO-101 trial of its lead candidate, ateganosine, as a treatment for advanced non-small cell lung cancer (NSCLC). Ateganosine is a novel dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. Ateganosine sequenced with a monoclonal antibody checkpoint inhibitor is being evaluated as a therapy for patients in ongoing Phase 2 and Phase 3 clinical trials.

MAIA obtained FDA clearance of its updated IND highlighting MAIA’s improved efficiencies to its manufacturing capabilities, including new manufacturers, formulation and storage conditions for ateganosine, and MAIA is now cleared to enroll patients in the U.S. for the expansion of the Phase 2 THIO-101 study of patients receiving advanced third-line (3L) NSCLC treatment. In addition to the U.S., the THIO-101 study is ongoing at 44 clinical sites in six countries. MAIA recently activated its first U.S. clinical site at Summit Medical Group in New Jersey.

In July 2025, the FDA granted Fast Track designation for ateganosine for the treatment of NSCLC. This designation allows for more frequent FDA communication, potential rolling review, and eligibility for Accelerated Approval and Priority Review. The additional data from the expansion studies may further support a filing for FDA Accelerated Approval.

“Up to five U.S. clinical sites are planned for THIO-101 Parts C and D this year, and we expect to activate a second U.S. site in the coming weeks,” said Vlad Vitoc, M.D., Founder and Chief Executive Officer of MAIA. “To date, data has shown overall survival (OS) beyond two years for eight patients treated with ateganosine in Parts A and B of THIO-101. We believe this bodes well for Parts C and D evaluations which are specific to third-line treatment care only, where the unmet need for improved clinical outcomes is most urgent.”

K. Robinson Lewis, Senior Vice President and Head of Regulatory and Quality for MAIA, commented, “We are excited about the prospects for our U.S. trials following FDA clearance of our amended IND. The unmet need for effective third-line NSCLC treatments is widespread in the U.S. Based on strong clinical data documented so far, we are confident in the potential of our therapy to address this significant and substantially underserved patient population.”

In parallel with THIO-101, MAIA is actively screening and enrolling patients in a pivotal Phase 3 clinical trial, THIO-104, designed to assess overall survival for ateganosine sequenced with a CPI compared to investigator’s choice of chemotherapy in a 1:1 randomization of up to 300 third-line NSCLC patients.

About Ateganosine

Ateganosine (THIO, 6-thio-dG or 6-thio-2’-deoxyguanosine) is a first-in-class investigational telomere-targeting agent currently in clinical development to evaluate its activity in non-small cell lung cancer (NSCLC). Telomeres, along with the enzyme telomerase, play a fundamental role in the survival of cancer cells and their resistance to current therapies. The modified nucleotide 6-thio-2’-deoxyguanosine induces telomerase-dependent telomeric DNA modification, DNA damage responses, and selective cancer cell death. Ateganosine-damaged telomeric fragments accumulate in cytosolic micronuclei and activates both innate (cGAS/STING) and adaptive (T-cell) immune responses. The sequential treatment of ateganosine followed by PD-(L)1 inhibitors resulted in profound and persistent tumor regression in advanced, in vivo cancer models by induction of cancer type–specific immune memory. Ateganosine is presently developed as a second or later line of treatment for NSCLC for patients that have progressed beyond the standard-of-care regimen of existing checkpoint inhibitors.

About THIO-101 Phase 2 Clinical Trial

THIO-101 is a multicenter, open-label, dose finding Phase 2 clinical trial. It is the first trial designed to evaluate ateganosine’s anti-tumor activity when followed by PD-(L)1 inhibition. The trial is testing the hypothesis that low doses of ateganosine administered prior to cemiplimab (Libtayo^®) will enhance and prolong immune response in patients with advanced NSCLC who previously did not respond or developed resistance and progressed after first-line treatment regimen containing another checkpoint inhibitor. The trial design has two primary objectives: (1) to evaluate the safety and tolerability of ateganosine administered as an anticancer compound and a priming immune activator (2) to assess the clinical efficacy of ateganosine using Overall Response Rate (ORR) as the primary clinical endpoint. The expansion of the study will assess overall response rates (ORR) in advanced NSCLC patients receiving third line (3L) therapy who were resistant to previous checkpoint inhibitor treatments (CPI) and chemotherapy. Treatment with ateganosine followed by cemiplimab (Libtayo^®) has shown an acceptable safety profile to date in a heavily pre-treated population. For more information on this Phase II trial, please visit ClinicalTrials.gov using the identifier NCT05208944.

About MAIA Biotechnology, Inc.

MAIA is a targeted therapy, immuno-oncology company focused on the development and commercialization of potential first-in-class drugs with novel mechanisms of action that are intended to meaningfully improve and extend the lives of people with cancer. Our lead program is ateganosine (THIO), a potential first-in-class cancer telomere targeting agent in clinical development for the treatment of NSCLC patients with telomerase-positive cancer cells. For more information, please visit www.maiabiotech.com.